The number of commercially insured patients who used indemnity plans in 1997 was drastically lower than it was in 1993, according to a new report from Mountain View, CA-based strategic research firm Frost & Sullivan.
The number of commercially insured patients who used indemnity plans in 1997 was drastically lower than it was in 1993, according to a new report from Mountain View, CA-based strategic research firm Frost & Sullivan.
According to the report, one out of two commercially insured individuals used a traditional indemnity plan in 1993. By 1997, that number had changed to almost one in ten.
The strength of managed care organizations, such as Aetna/US Healthcare, CIGNA Corp. and Kaiser was the primary factor behind the shift.
Although government and traditional indemnity insurers remain important sources of drug reimbursement, managed care organizations accounted for $24.9 billion of the $48.1 billion reimbursed last year.
"The most important issue facing the pharmaceutical manufacturers is ensuring that their drug is accepted by managed care organizations," said Marina Ulmishek, medical analyst at Frost & Sullivan. "It's imperative that competitors understand the process of how managed care organizations make drug-related decisions and what factors have the greatest influence over these decisions."
Also noted in the report were the climbing populations of uninsured, elderly and disabled patients.
Many of these individuals are currently covered by federal Medicare and Medicaid programs, but how those programs actually work - and how they reimburse for prescription products - may undergo a transformation as the number and needs of insured patients grow.
Ulmishek said: "As out-of-pocket payments continue to fall, companies must anticipate how different sources of reimbursement will influence their markets." PR
Reshema Kemps-Polanco: Taking Risks for Greater Reward
May 14th 2025Reshema Kemps-Polanco, executive VP and chief commercial officer, Novartis US, and the 2025 Healthcare Businesswomen’s Association Woman of the Year, uses the lessons she learned from her family to bring out the best in her teams.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Novo Nordisk’s Sogroya Demonstrates Efficacy in Children with Growth Disorders
May 14th 2025Results from the Phase III REAL8 basket study found that once-weekly Sogroya was effective in children with growth disorders, including those born small for gestational age, with Noonan syndrome, or idiopathic short stature.